ClinicalTrials.gg
TerminatedNCT00434096Updated Jul 20, 2009

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

A Phase 3 interventional study of rimonabant (SR141716) and placebo in Obesity, sponsored by Sanofi. Terminated at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2009-07-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision taken in light of demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
915
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.

Enrollment
7th of 21
915 · median 643
Started
2007
with 5 others
Phase 3
18 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
19 of 21
Sanofi

Among the 21 studies testing rimonabant in Obesity, this one is the 7th largest by enrollment, is one of 6 that started in 2007, is one of 18 in phase 3, and was the 12th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing rimonabant in Obesity as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks.

Secondary objectives are:

  • To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL-cholesterol and visceral fat area.
  • To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks.
  • To evaluate the pharmacokinetics of SR141716.
03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity disease
  • cannabinoid-1 receptor
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) > 25 kg/m²
  • Visceral Fat Area (VFA) > 100 cm²
  • Triglycerides (TG) > 150 mg/dL and \< 700 mg/dL, and/or HDL-cholesterol \< 40 mg/dL(Dyslipidemia)
  • At least 1 criteria of the following 2 comorbidities:

    • Impaired Glucose Tolerance or Type 2 diabetes
    • Hypertension

Exclusion criteria

Exclusion Criteria:

  • Patient with a secondary obesity.
  • Patients who have received the diet therapy for less than 8 weeks before start of the observation period.
  • Patients whose body weight changed by more than the variation of ± 2kg for screening period.
  • Low compliance to drug intake (\< 80%) and dietary instruction during the observation period.
  • Patients with type 1 diabetes.
  • Patients with a primary hyperlipidemia (i.e., familial hypercholesterolemia, familial combined hyperlipidemia and familial type III hyperlipidemia).
  • Patients with a LDL-cholesterol > 190 mg/dL at any of Weeks -8 or -4.
  • Patients with a secondary hypertension.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
915 participants (actual)

Study arms

  • Experimental
    1

    Drug: rimonabant (SR141716)

  • Placebo comparator
    2

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. body weight: relative change from baseline

    Time frame: Week 52

  2. triglycerides: relative change from baseline

    Time frame: Week 52

Secondary outcomes

  1. HDL-cholesterol ;visceral fat area

    Time frame: Week 52

  2. Safety: Adverse events

    Time frame: study period

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Nov 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2007
First posted
Feb 12, 2007
Start
Feb 2007
Primary completionActual
Nov 2008
CompletionActual
Feb 2009
Last update
Jul 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00434096
Lead sponsor
Sanofi
First posted
Feb 12, 2007
Start date
Feb 2007
Primary completion
Nov 2008
Completion
Feb 2009
Last update
Jul 20, 2009

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion